Ionis Net Tangible Assets from 2010 to 2026
| IONS Stock | USD 86.50 3.02 3.62% |
Net Tangible Assets | First Reported 2010-06-30 | Previous Quarter 486.6 M | Current Value 428.3 M | Quarterly Volatility 391.8 M |
Check Ionis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ionis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.6 M, Interest Expense of 109.2 M or Total Revenue of 851.5 M, as well as many indicators such as Price To Sales Ratio of 16.15, Dividend Yield of 0.0 or PTB Ratio of 9.71. Ionis financial statements analysis is a perfect complement when working with Ionis Pharmaceuticals Valuation or Volatility modules.
Ionis | Net Tangible Assets | Build AI portfolio with Ionis Stock |
The evolution of Net Tangible Assets for Ionis Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Ionis Pharmaceuticals compares to historical norms and industry peers.
Latest Ionis Pharmaceuticals' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Ionis Pharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Ionis Pharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ionis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Ionis Net Tangible Assets Regression Statistics
| Arithmetic Mean | 507,227,793 | |
| Geometric Mean | 389,930,875 | |
| Coefficient Of Variation | 71.34 | |
| Mean Deviation | 279,054,393 | |
| Median | 531,922,431 | |
| Standard Deviation | 361,842,564 | |
| Sample Variance | 130930T | |
| Range | 1.4B | |
| R-Value | 0.52 | |
| Mean Square Error | 101356.9T | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | 37,525,409 | |
| Total Sum of Squares | 2094880.7T |
Ionis Net Tangible Assets History
About Ionis Pharmaceuticals Financial Statements
Ionis Pharmaceuticals shareholders use historical fundamental indicators, such as Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Ionis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Ionis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Ionis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 658.8 M | 531.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.